17β-hydroxysteroid dehydrogenase type 14 is a predictive marker for tamoxifen response in oestrogen receptor positive breast cancer

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Sivik, Tove ^a   Gunnarsson, Cecilia ^a,b   Fornander, Tommy ^c   Nordenskjöld, Bo ^a,b   Skoog, Lambert ^c   Stål, Olle ^a,b   Jansson, Agneta ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b Department of Clinical Immunology and Transfusion Medicine   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

17BETA HYDROXYSTEROID DEHYDROGENASE TYPE 14; BIOLOGICAL MARKER; TAMOXIFEN; TESTOSTERONE 17BETA DEHYDROGENASE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; CONTROLLED STUDY; DRUG RESPONSE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PROTEIN EXPRESSION; TISSUE MICROARRAY;

17-HYDROXYSTEROID DEHYDROGENASES; ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTORS, ESTROGEN; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84863707833     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040568     Document Type: Article

References (18)

1. Labrie F, Belanger A, Simard J, LuuThe V, Labrie C, (1995) DHEA and peripheral androgen and estrogen formation: Intracrinology. In: Bellino FL, Daynes RA, Hornsby PJ, Lavrin DH, Nestler JE, editors. pp. 16-28 editors. Dehydroepiandrosterone. New York: New York Acad Sciences. pp.
2. Day JM, Tutill HJ, Purohit A, Reed MJ, (2008) Design and validation of specific inhibitors of 17β-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis. Endocrine-Related Cancer 15: 665-692.
3. Gunnarsson C, Ahnström M, Kirschner K, Olsson B, Nordenskjöld B, et al. (2003) Amplification of HSD17B1 and ERBB2 in primary breast cancer. Oncogene 22: 34-40.
4. Gunnarsson C, Jerevall PL, Hammar K, Olsson B, Nordenskjöld B, et al. (2008) Amplification of HSD17B1 has prognostic significance in postmenopausal breast cancer. Breast Cancer Research and Treatment 108: 35-41.
5. Gunnarsson C, Olsson BM, Stål O, Arnesson LG, Nordenskjöld B, et al. (2001) Abnormal expression of 17β-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence. Cancer Research 61: 8448-8451.
6. Oduwole OO, Li Y, Isomaa VV, Mäntyniemi A, Pulkka AE, et al. (2004) 17β-Hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer. Cancer Research 64: 7604-7609.
7. Lukacik P, Keller B, Bunkoczi G, Kavanagh KL, Lee WH, et al. (2007) Structural and biochemical characterization of human orphan DHRS10 reveals a novel cytosolic enzyme with steroid dehydrogenase activity. The Biochemical journal 402: 419-427.
8. Jansson AK, Gunnarsson C, Cohen M, Sivik T, Stål O, (2006) 17β-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer. Cancer Research 66: 11471-11477.
9. Jansson A, Delander L, Gunnarsson C, Fornander T, Skoog L, et al. (2009) Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients. Clinical Cancer Research 15: 3610-3616.
10. Rutqvist LE, Johansson H, (2007) Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta oncologica 46: 133-145.
11. Khoshnoud MR, Lofdahl B, Fohlin H, Fornander T, Stal O, et al. (2011) Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen. Breast Cancer Research and Treatment.
12. Lonning PE, Dowsett M, Powles TJ, (1990) Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer. J Steroid Biochem 35: 355-366.
13. Key T, Appleby P, Barnes I, Reeves G, (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94: 606-616.
14. van Landeghem AA, Poortman J, Nabuurs M, Thijssen JH, (1985) Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res 45: 2900-2906.
15. Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378: 771-784.
16. Pasqualini JR, (2009) Progestins in the menopause in healthy women and breast cancer patients. Maturitas 62: 343-348.
17. Iino Y, Wolf DM, Langan-Fahey SM, Johnson DA, Ricchio M, et al. (1991) Reversible control of oestradiol-stimulated growth of MCF-7 tumours by tamoxifen in the athymic mouse. Br J Cancer 64: 1019-1024.
18. Saijo K, Collier JG, Li AC, Katzenellenbogen JA, Glass CK, (2011) An ADIOL-ERbeta-CtBP transrepression pathway negatively regulates microglia-mediated inflammation. Cell 145: 584-595.